April 14, 2023
Novocure Announces 27 Presentations, Including Real-World Evidence and Preclinical Research, at American Association for Cancer Research (AACR) Annual Meeting 2023
ROOT, Switzerland–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) today announced 27 presentations on Tumor Treating Fields (TTFields) will be delivered at the American Association for Cancer Research (AACR) Annual Meeting 2023, to be held April 14 to 19 in Orlando, Florida. The research described in the presentations includes real-world evidence supporting… Read More
learn more
April 3, 2023
Novocure to Report First Quarter 2023 Financial Results
ROOT, Switzerland–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that it will report financial results for the first quarter 2023 on Thursday, May 4, 2023, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss the company’s financial results for the three months… Read More
learn more
March 29, 2023
Kristin Stafford Joins Novocure Board of Directors
ROOT, Switzerland–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) today announced that Kristin Stafford has been elected to Novocure’s Board of Directors. “We look forward to welcoming Ms. Stafford to our board of directors,” said William Doyle, Novocure’s Executive Chairman. “Her broad expertise in finance in the life sciences sector and experience… Read More
learn more
March 16, 2023
Novocure Announces 5th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program
ROOT, Switzerland–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) today announced the 5th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program. The program represents a joint effort with the American Association for Cancer Research (AACR) to promote and support innovative research on Tumor Treating Fields (TTFields) as well as to encourage… Read More
learn more
March 1, 2023
Novocure Announces Reimbursement of Optune® for the Treatment of Newly Diagnosed Glioblastoma in France
Optune is now available as a treatment for newly diagnosed glioblastoma patients in France ROOT, Switzerland–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) today announced the reimbursement and availability of Optune together with temozolomide (TMZ) for the treatment of adult patients with newly diagnosed glioblastoma (GBM) in France. The order registering… Read More
learn more
March 1, 2023
Novocure Announces Last Patient Enrolled in Pivotal METIS Study of Tumor Treating Fields in Brain Metastases from Non-Small Cell Lung Cancer
Final data from the METIS study anticipated in 2024 ROOT, Switzerland–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) today announced that the final patient has enrolled in the pivotal METIS study evaluating the efficacy of Tumor Treating Fields (TTFields) therapy following stereotactic radiosurgery (SRS) for treatment of patients with… Read More
learn more
February 23, 2023
Novocure Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update
Full year 2022 net revenues of $538 million and fourth quarter net revenues of $128 million Pivotal LUNAR study in non-small cell lung cancer met primary overall survival endpoint and a key secondary overall survival endpoint Novocure completes enrollment of pivotal PANOVA-3 study in pancreatic… Read More
learn more
February 23, 2023
Allyson J. Ocean, M.D., Joins Novocure Board of Directors
Dr. Ocean, a medical oncologist and Associate Professor of Clinical Medicine at Weill Cornell Medicine, brings decades of experience in oncology to Novocure ROOT, Switzerland–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) today announced that Allyson J. Ocean, M.D., has been elected to Novocure’s Board of Directors. “We are honored… Read More
learn more
February 15, 2023
Novocure Announces Last Patient Enrolled in Pivotal PANOVA-3 Study of Tumor Treating Fields in Pancreatic Cancer
Final data from the PANOVA-3 study anticipated in 2024 ROOT, Switzerland–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) today announced that the final patient has been enrolled in the pivotal PANOVA-3 study evaluating the efficacy of Tumor Treating Fields (TTFields) together with nab-paclitaxel and gemcitabine for treatment of patients… Read More
learn more
January 19, 2023
Novocure Announces Organizational Changes to Prepare for Future Growth
ROOT, Switzerland–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced organizational changes to prepare for future growth, effective Jan. 17. Pritesh Shah, Novocure’s Chief Commercial Officer, will transition into a new executive role as Chief Growth Officer. In this role, Mr. Shah will have worldwide responsibilities for product and portfolio strategy, brand… Read More
learn more